購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huDR3(TNFRSF25) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huDR3(TNFRSF25) Mouse
製品名
huDR3(TNFRSF25) Mouse
製品ID
C002066
系統名
C57BL/6NCya-Tnfrsf25tm1(hTNFRSF25)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huDR3(TNFRSF25) Mouse(カタログ番号C002066)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, GEF720, WSL-LR, PLEKHG5, TNFRSF12
NCBI ID
染色体
Chr 1
MGI ID
さらに
系統詳細
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25), also known as death receptor 3 (DR3), is a member of the tumor necrosis factor receptor (TNFR) superfamily and serves as the specific receptor for TNFSF15 (TL1A). It plays a critical role in immune homeostasis regulation, inflammatory responses, and apoptosis. This receptor contains a death domain and can specifically bind to its ligand TL1A. Upon binding, it recruits downstream adaptor molecules to activate NF-κB and MAPK signaling pathways, or induce apoptosis, thereby participating in the regulation of T cell proliferation and differentiation—particularly Th2 and Th17 cells—regulatory T cell (Treg) expansion, and tissue inflammatory responses [1]. TNFRSF25 is primarily expressed in lymphocyte-rich tissues, such as the spleen, thymus, and lymph nodes. It is highly expressed on the surface of activated T cells, NKT cells, and certain innate lymphoid cells, and can also be detected in mucosal tissues such as the intestine and lungs, suggesting its important role in mucosal immunity and inflammation regulation [2].
Abnormal activation of the TNFRSF25/TL1A signaling pathway is closely associated with the development of various inflammatory and autoimmune diseases, with particularly prominent roles in inflammatory bowel disease (IBD), allergic asthma, and psoriasis. Studies have shown that in inflammatory bowel disease, TNFRSF25 signaling promotes Th17 cell activation and amplifies intestinal inflammation, and is also involved in fibrosis processes. In allergic asthma, this pathway enhances Th2-type immune responses and airway inflammation [1,3]. Based on its critical role in immune regulation, TNFRSF25 has become a highly promising therapeutic target in the field of immunotherapy for inflammatory and autoimmune diseases. Anti-TL1A monoclonal antibodies have demonstrated favorable efficacy in clinical trials for IBD [4-5].
huDR3(TNFRSF25) mice are humanized models constructed using gene editing technology. In this model, the sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene. huDR3(TNFRSF25) mice can be used for preclinical studies on the pathogenesis of autoimmune and inflammatory diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis, as well as for the evaluation of DR3-targeted drugs.
参考文献
Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 2008;205(5):1037-1048.
Meylan F, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4(2):172-185.
Clarke AW, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10(5):664-677.
Sands BE, et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024.
Feagan BG, et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol. 2025.
系統作製戦略
The sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene.

Figure 1. Gene editing strategy of huDR3(TNFRSF25) mice.
適用分野
The screening, development, and preclinical evaluation of TNFRSF25-targeted drugs;
Research on the pathogenesis and treatment of autoimmune diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis;
Research on the mechanism of the TNFRSF25/TL1A signaling pathway.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
